Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Multimarker Testing Procedure Developed for Rapid DOA Screening

By LabMedica International staff writers
Posted on 03 Dec 2009
A multimarker drugs-of-abuse (DOA) testing procedure has been developed for rapid drug screening programs.

DOA biochips permit the analysis of up to 10 drug classes from a single patient sample, providing rapid and accurate testing. More...
The biochip array technology is based on enzyme-linked immunosorbant assay (ELISA) procedures.

The new drugs-of-abuse testing methods were developed Randox Laboratories (Crumlin, UK), a privately owned diagnostic reagent and equipment manufacturing company. The DOA biochips permit the analysis of up to 10 drug classes from a single patient sample, providing rapid and accurate testing.

Each 9 mm x 9 mm biochip comprises up to 25 discrete test regions on which immobilized antibodies specific to each biomarker are contained. Two DTRs are reserved for quality control testing.

The DOA biochip arrays developed by Randox demonstrate good assay performance and correlation with gas chromatography-mass spectrometry (GC/MS), according to the company.

Two DOA biochip arrays, both validated for use with urine and whole blood, are available: DOA array I contains amphetamine, methamphetamine, barbiturates, benzodiazepine 1 and 2, cannabinoids, cocaine metabolite, methadone, opiates, and phencyclidine; DOA array II enables testing for buprenorphine, fentanyl, generic opioids, ketamine, d-lysergic acid diethylamide (LSD), 3,4-methylenedioxy-N-methylamphetamine (MDMA)-commonly known as ecstasy, methaqualone, oxycodone 1 and 2, and propoxyphene. Creatinine is included on the arrays as a marker of adulteration when testing urine samples.

The use of oral fluid as a sample matrix is validated on DOA array I, and is currently in development for DOA array II.

Three biochip analyzers have been developed and can be employed for the DOA arrays. The fully automated Evidence was designed for high-throughput laboratories and requires as little as seven μL of urine for all 10 drug classes. This rapid testing platform generates 1,088 tests per hour. Once samples are loaded onto the Evidence, the doors are locked and the PC interface is password protected, providing chain-of-custody information.

The semi-automated Evidence Investigator for medium-sized laboratories and the point-of-application Evidence Multistat analyzer, which generates results in 20 minutes, are also available.

Related Links:
Randox Laboratories


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.